REGENXBIO Company Profile (NASDAQ:RGNX)

About REGENXBIO

REGENXBIO logoREGENXBIO Inc. is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors). Its NAV Technology Platform is applied in the development of approximately 30 product candidates for a range of diseases, including over five internally developed product candidates and approximately 20 partnered product candidates developed by its NAV Technology Licensees. Its therapeutic programs include RGX-501 for Homozygous familial hypercholesterolemia (HoFH); RGX-111 for Mucopolysaccharidosis Type I (MPS I); RGX-121 for Mucopolysaccharidosis Type II (MPS II); RGX-314 for Wet age related macular degeneration (wet AMD), and RGX-321 for X-linked retinitis pigmentosa (XLRP).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RGNX
  • CUSIP:
Key Metrics:
  • Previous Close: $17.30
  • 50 Day Moving Average: $18.74
  • 200 Day Moving Average: $17.00
  • 52-Week Range: $7.07 - $24.55
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.41
  • P/E Growth: 0.00
  • Market Cap: $458.02M
  • Outstanding Shares: 26,475,000
  • Beta: -0.58
Profitability:
  • Net Margins: -661.81%
  • Return on Equity: -24.21%
  • Return on Assets: -23.16%
Debt:
  • Current Ratio: 6.72%
  • Quick Ratio: 6.72%
Additional Links:
Companies Related to REGENXBIO:

Analyst Ratings

Consensus Ratings for REGENXBIO (NASDAQ:RGNX) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $30.50 (76.30% upside)

Analysts' Ratings History for REGENXBIO (NASDAQ:RGNX)
Show:
DateFirmActionRatingPrice TargetDetails
11/13/2016Piper Jaffray CompaniesReiterated RatingBuy$25.00View Rating Details
8/22/2016Chardan CapitalReiterated RatingBuyView Rating Details
4/8/2016Morgan StanleyBoost Price Target$34.00 -> $36.00View Rating Details
10/12/2015Bank of America CorpInitiated CoverageBuy$29.00View Rating Details
(Data available from 2/21/2015 forward)

Earnings

Earnings History for REGENXBIO (NASDAQ:RGNX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2017        
5/5/2016($0.40)($0.41)ViewN/AView Earnings Details
3/3/2016Q415($0.34)($0.20)$1.23 million$4.40 millionViewN/AView Earnings Details
11/5/2015Q315($0.35)($1.52)$1.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for REGENXBIO (NASDAQ:RGNX)
Current Year EPS Consensus Estimate: $-2.19 EPS
Next Year EPS Consensus Estimate: $-2.70 EPS

Dividends

Dividend History for REGENXBIO (NASDAQ:RGNX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for REGENXBIO (NASDAQ:RGNX)
Insider Ownership Percentage: 21.00%
Institutional Ownership Percentage: 64.31%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/17/2016Fmr LlcInsiderSell18,300$12.41$227,103.00View SEC Filing  
5/16/2016Fmr LlcInsiderSell16,030$11.65$186,749.50View SEC Filing  
5/12/2016Fmr LlcInsiderSell6,711$10.85$72,814.35View SEC Filing  
5/11/2016Fmr LlcInsiderSell25,132$10.36$260,367.52View SEC Filing  
5/9/2016Fmr LlcInsiderSell10,570$9.94$105,065.80View SEC Filing  
5/4/2016Fmr LlcInsiderSell1,896$10.51$19,926.96View SEC Filing  
5/3/2016Fmr LlcInsiderSell6,046$10.76$65,054.96View SEC Filing  
4/29/2016Fmr LlcInsiderSell4,723$10.80$51,008.40View SEC Filing  
4/28/2016Fmr LlcInsiderSell33,196$11.23$372,791.08View SEC Filing  
4/26/2016Fmr LlcInsiderSell9,188$11.19$102,813.72View SEC Filing  
4/22/2016Fmr LlcInsiderSell20,558$11.30$232,305.40View SEC Filing  
4/20/2016Fmr LlcInsiderSell13,189$11.66$153,783.74View SEC Filing  
4/18/2016Fmr LlcInsiderSell18,900$11.75$222,075.00View SEC Filing  
4/14/2016Fmr LlcInsiderSell27,036$11.46$309,832.56View SEC Filing  
9/22/2015James E FlynnInsiderBuy175,000$22.00$3,850,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for REGENXBIO (NASDAQ:RGNX)
DateHeadline
bizjournals.com logoRockville gene therapy company to begin trials for treatment for leading cause of blindness (NASDAQ:RGNX)
www.bizjournals.com - February 16 at 7:11 PM
us.rd.yahoo.com logoREGENXBIO Announces IND Active for Phase I Trial of RGX-314 to Treat Wet Age-Related Macular Degeneration (NASDAQ:RGNX)
us.rd.yahoo.com - February 15 at 12:49 AM
finance.yahoo.com logoREGENXBIO to Present at the 6th Annual LEERINK Partners Global Healthcare Conference (NASDAQ:RGNX)
finance.yahoo.com - February 9 at 11:11 PM
finance.yahoo.com logoREGENXBIO to Participate in the SunTrust Robinson Humphrey 2017 Orphan Drug Day (NASDAQ:RGNX)
finance.yahoo.com - February 2 at 11:42 PM
News IconRegenxBio Inc RGNX Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:RGNX)
www.bioportfolio.com - January 14 at 7:34 PM
marketexclusive.com logoREGENXBIO INC. (NASDAQ:RGNX) Files An 8-K Results of Operations and Financial Condition (NASDAQ:RGNX)
marketexclusive.com - January 7 at 1:35 AM
biz.yahoo.com logoREGENXBIO INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statements (NASDAQ:RGNX)
us.rd.yahoo.com - January 6 at 8:33 PM
capitalcube.com logoREGENXBIO, Inc. – Value Analysis (NASDAQ:RGNX) : December 23, 2016 (NASDAQ:RGNX)
www.capitalcube.com - December 23 at 7:38 PM
capitalcube.com logoREGENXBIO, Inc. breached its 50 day moving average in a Bearish Manner : RGNX-US : December 22, 2016 (NASDAQ:RGNX)
www.capitalcube.com - December 22 at 7:53 PM
insidermonkey.com logoHedge Funds Are Betting On Regenxbio Inc (RGNX) (NASDAQ:RGNX)
www.insidermonkey.com - December 8 at 7:59 PM
us.rd.yahoo.com logo8:03 am REGENXBIO announces that Voyager Therapeutics (VYGR (NASDAQ:RGNX)
us.rd.yahoo.com - December 1 at 8:22 AM
capitalcube.com logoETFs with exposure to REGENXBIO, Inc. : November 23, 2016 (NASDAQ:RGNX)
www.capitalcube.com - November 23 at 7:25 PM
capitalcube.com logoREGENXBIO, Inc. :RGNX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21, 2016 (NASDAQ:RGNX)
www.capitalcube.com - November 21 at 12:30 PM
finance.yahoo.com logoREGENXBIO INC. Financials (NASDAQ:RGNX)
finance.yahoo.com - November 17 at 6:51 PM
finance.yahoo.com logoREGENXBIO to Present at the 28th Annual Piper Jaffray Healthcare Conference (NASDAQ:RGNX)
finance.yahoo.com - November 17 at 6:51 PM
einnews.com logoREGENXBIO Reports Third Quarter 2016 Financial Results and Recent Operational Highlights (NASDAQ:RGNX)
uspolitics.einnews.com - November 10 at 10:22 AM
sg.finance.yahoo.com logoRegenxbio reports 3Q loss (NASDAQ:RGNX)
sg.finance.yahoo.com - November 9 at 7:09 PM
biz.yahoo.com logoQ3 2016 Regenxbio Inc Earnings Release - Before Market Open (NASDAQ:RGNX)
biz.yahoo.com - November 9 at 9:47 AM
publicnow.com logoREGENXBIO to Host Conference Call on November 9 to Discuss Third Quarter 2016 Financial Results and Recent Operational Highlights (NASDAQ:RGNX)
www.publicnow.com - November 2 at 10:42 AM
publicnow.com logoREGENXBIO to Present at the Jefferies Gene Editing and Gene Therapy Summit (NASDAQ:RGNX)
www.publicnow.com - October 4 at 6:38 PM
4-traders.com logoREGENXBIO : Publishes Data from Ongoing Preclinical Studies of NAV Gene Therapy in Neurodegenerative Diseases (NASDAQ:RGNX)
www.4-traders.com - September 16 at 10:35 AM
streetinsider.com logoRegenxbio (RGNX) Issues Update on NAV Gene Therapy for MPS I, MPS II (NASDAQ:RGNX)
www.streetinsider.com - September 13 at 11:55 AM
finance.yahoo.com logoREGENXBIO Publishes Data from Ongoing Preclinical Studies of NAV® Gene Therapy in Neurodegenerative Diseases (NASDAQ:RGNX)
finance.yahoo.com - September 13 at 11:55 AM
finance.yahoo.com logo7:10 am REGENXBIO publishes data from ongoing preclinical studies of NAV gene therapy in neurodegenerative diseases in the Molecular Genetics & Metabolism Journal (NASDAQ:RGNX)
finance.yahoo.com - September 13 at 11:55 AM
biz.yahoo.com logoREGENXBIO INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:RGNX)
biz.yahoo.com - September 12 at 6:41 PM
finance.yahoo.com logoREGENXBIO to Participate in Global Healthcare Conferences (NASDAQ:RGNX)
finance.yahoo.com - September 7 at 7:09 PM
4-traders.com logoRegenxbio : Daniel Tass Appointed to REGENXBIO Board of Directors (NASDAQ:RGNX)
www.4-traders.com - August 19 at 10:04 AM
publicnow.com logoDaniel Tassé Appointed to REGENXBIO Board of Directors (NASDAQ:RGNX)
www.publicnow.com - August 16 at 10:27 AM
biz.yahoo.com logoREGENXBIO INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits (NASDAQ:RGNX)
biz.yahoo.com - August 16 at 10:27 AM
finance.yahoo.com logoEdited Transcript of RGNX earnings conference call or presentation 9-Aug-16 12:30pm GMT (NASDAQ:RGNX)
finance.yahoo.com - August 10 at 10:14 AM
globenewswire.com logoREGENXBIO Reports Second Quarter 2016 Financial Results and Recent Operational Highlights (NASDAQ:RGNX)
globenewswire.com - August 9 at 10:18 AM
cnbc.com logoRegenxbio reports 2Q loss (NASDAQ:RGNX)
www.cnbc.com - August 9 at 10:18 AM
biz.yahoo.com logoRegenxbio Inc Earnings Call scheduled for 8:30 am ET today (NASDAQ:RGNX)
biz.yahoo.com - August 9 at 10:18 AM
publicnow.com logoDaniel J. Abdun-Nabi Appointed to REGENXBIO Board of Directors (NASDAQ:RGNX)
www.publicnow.com - August 8 at 7:20 PM
publicnow.com logoFDA Grants Rare Pediatric Disease Designation to REGENXBIO's RGX-121 Gene Therapy for the Treatment of Mucopolysaccharidosis Type II (MPS II) (NASDAQ:RGNX)
www.publicnow.com - August 2 at 12:04 PM
biz.yahoo.com logoREGENXBIO INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:RGNX)
biz.yahoo.com - August 2 at 12:04 PM
publicnow.com logoREGENXBIO to Host Conference Call on August 9 to Discuss Second Quarter 2016 Financial Results and Recent Operational Highlights (NASDAQ:RGNX)
www.publicnow.com - August 1 at 6:53 PM
benzinga.com logoCould Regenxbio Shares Have 320% Upside? (NASDAQ:RGNX)
www.benzinga.com - July 8 at 10:00 AM
insidermonkey.com logoThis Protocol Change Means Regenxbio Inc (RGNX) Can Finally Get Started On Its Gene Therapy Trial (NASDAQ:RGNX)
www.insidermonkey.com - July 7 at 2:17 PM
marketexclusive.com logoThis Protocol Change Means Regenxbio Inc (NASDAQ:RGNX) Can Finally Get Started On Its Gene Therapy Trial (NASDAQ:RGNX)
marketexclusive.com - July 6 at 7:25 PM
publicnow.com logoREGENXBIO Provides Update on Lead Gene Therapy Development Programs (NASDAQ:RGNX)
www.publicnow.com - July 5 at 4:21 PM
capitalcube.com logoETF’s with exposure to REGENXBIO, Inc. : June 20, 2016 (NASDAQ:RGNX)
www.capitalcube.com - June 20 at 3:08 PM
biz.yahoo.com logoREGENXBIO INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:RGNX)
biz.yahoo.com - June 1 at 4:31 PM
capitalcube.com logoETF’s with exposure to REGENXBIO, Inc. : May 23, 2016 (NASDAQ:RGNX)
www.capitalcube.com - May 23 at 5:33 PM
capitalcube.com logoREGENXBIO, Inc. :RGNX-US: Earnings Analysis: Q1, 2016 By the Numbers (NASDAQ:RGNX)
www.capitalcube.com - May 17 at 3:53 PM
News IconMix Wondering Stocks- Southwest Airlines (NYSE:LUV), Regenxbio (NASDAQ:RGNX), Williams Companies (NYSE ... - Seneca Globe (NASDAQ:RGNX)
www.senecaglobe.com - May 17 at 12:41 PM
streetinsider.com logoRegenxbio (RGNX), Biogen (BIIB) Enter Licensing Agreement for Gene Therapy Treatments - StreetInsider.com (NASDAQ:RGNX)
www.streetinsider.com - May 17 at 12:41 PM
bizjournals.com logoAmgen signs licensing deal for Penn gene therapy technology (NASDAQ:RGNX)
www.bizjournals.com - May 16 at 10:55 AM
publicnow.com logoREGENXBIO and Biogen Enter Exclusive License Agreement for the Development of Gene Therapy Treatments for Rare Genetic Vision Disorders (NASDAQ:RGNX)
www.publicnow.com - May 16 at 7:32 AM
News IconEarnings Outlook on Regenxbio Inc (NASDAQ:RGNX) - B.O.D.Y Confidential (NASDAQ:RGNX)
www.bodyconfidential.com - May 7 at 11:39 AM

Social

What is REGENXBIO's stock symbol?

REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX."

Where is REGENXBIO's stock going? Where will REGENXBIO's stock price be in 2017?

2 analysts have issued 1-year target prices for REGENXBIO's stock. Their predictions range from $25.00 to $36.00. On average, they expect REGENXBIO's share price to reach $30.50 in the next year.

When will REGENXBIO announce their earnings?

REGENXBIO is scheduled to release their next quarterly earnings announcement on Wednesday, March, 1st 2017.

Who owns REGENXBIO stock?

REGENXBIO's stock is owned by a number of of institutional and retail investors. Top institutional investors include Bain Capital Public Equity Management LLC (9.42%), FMR LLC (8.63%), Perceptive Advisors LLC (4.84%), Franklin Resources Inc. (3.68%), Vivo Capital LLC (1.90%) and State Street Corp (1.16%). Company insiders that own REGENXBIO stock include Fmr Llc and James E Flynn.

Who sold REGENXBIO stock? Who is selling REGENXBIO stock?

REGENXBIO's stock was sold by a variety of institutional investors in the last quarter, including Vivo Capital LLC, FIL Ltd and Franklin Resources Inc..

Who bought REGENXBIO stock? Who is buying REGENXBIO stock?

REGENXBIO's stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Perceptive Advisors LLC, Nicholas Investment Partners LP, Russell Investments Group Ltd., State Street Corp, Bain Capital Public Equity Management LLC and RTW Investments LP.

How do I buy REGENXBIO stock?

Shares of REGENXBIO can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of REGENXBIO stock cost?

One share of REGENXBIO stock can currently be purchased for approximately $17.30.

REGENXBIO (NASDAQ:RGNX) Chart for Tuesday, February, 21, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for REGENXBIO (NASDAQ:RGNX)

Earnings History Chart

Earnings by Quarter for REGENXBIO (NASDAQ:RGNX)

Dividend History Chart

Dividend Payments by Quarter for REGENXBIO (NASDAQ:RGNX)

Last Updated on 2/21/2017 by MarketBeat.com Staff